New Report: Global Ischemic Heart Disease (IHD)Drugs Market 2015-2019

About IHD
IHD is an abnormal condition of the human body marked by narrowing or blocking of the arteries that supply blood to the heart. It results from the buildup of plaque in the arteries. The condition often arises during excitement and exertion when heart requires more blood supply. This leads to recurrent chest pain and discomfort due to lack of sufficient blood supply, a condition known as angina pectoris.

Prolonged blockage of the arteries due to lack of blood supply may result in death of tissues in the heart, leading to myocardial infarction. The symptoms develop slowly, and in most cases the condition is asymptomatic until it reaches the last stages. The common indications include chest pain and shortness of breath. Treatment options are available depending on the condition of the patient. A range of medications of different classes, such as statins, antiplatelet drugs, nitrates, beta-blockers, etc. can be chosen from. Surgical procedures, such as angioplasty and coronary artery bypass graft, are also opted in serious scenarios.

The report’s analysts forecast the global IHD drugs market to grow at a CAGR of 3.61% during 2014-2019.

Covered in this Report
The report covers the present scenario and the growth prospects of the global IHD drugs market for the period 2015-2019. To calculate the market size, we consider the revenue generated from the sales of various branded therapies and generics, along with the drugs used as off-label for the treatment of IHD. IHD includes:
- Angina pectoris
- Myocardial infarction.

The Technavio report, namely Global IHD Drugs Market 2015-2019, is based on an in-depth market analysis, with inputs from industry experts. We covers the Americas, APAC and EMEA markets. We also discuss the key vendors operating in this market.

Key Regions
- Americas
- EMEA        
- APAC

Key Vendors
- AstraZeneca
- Bayer
- Eli Lilly
- Novartis
- Pfizer
- Sanofi

Other Prominent Vendors
 
- Actelion
- Amgen
- Baxter
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Daiichi-Sankyo
- Eisai
- F.Hoffmann-La Roche
- Gilead Sciences
- GlaxoSmithKline
- Human Stem Cells Institute
- Janssen Pharmaceuticals
- Juventas Therapeutics
- Lacer
- Merck
- Nuo Therapeutics
- Ono Pharmaceutical
- Pharmahungary Group
- Resverlogix
- Takeda Pharmaceutical Company
- Taxus Cardium
- The Medicines Company
- United Therapeutics

Market Driver
- Rise in Number of Patients
- For a full and detailed list, view our report

Market Challenge
- Delayed Diagnosis
- For a full and detailed list, view our report

Market Trend
- Increase in Health Awareness
- For a full and detailed list, view our report

Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

thttp://www.marketresearchint.com/pharmaceutical-market-research-reports/global-ischemic-heart-disease-ihddrugs-market-2015-2019.html